Leo Pharma is on track for a record year  

Overall sales growth Jan-July for Danish pharmaceutical company Leo Pharma is around 10%, and extended collaboration with US company has been announced

Danish pharmaceutical company Leo Pharma could be on its way to a record year for revenues and profits. The company is budgeting for a pre-tax profit of DKK 2 bn (USD 320 mn) compared to DKK 1.9 bn (USD 304 mn) last year. "An impressive figure on a turnover of slightly over DKK 4 bn (USD 640 mn)," writes financial daily newspaper Børsen which reports the news. Over the period January to July, overall sales growth rate is in the region of 10%.

Leo Pharma announced a few days ago that it has extended its collaboration with the US pharmaceutical company Warner Chilcott. The US company is currently marketing Leo Pharma's drug Dovonex for the treatment of psoriasis under a co-promotion with Bristol-Myers Squibb. With the extended collaboration, Warner Chilcott licenses the full portfolio of Leo Pharma's psoriasis products in the US.

Leo Pharma is headquartered in Ballerup near Copenhagen and employs 3,300 people in more than 40 countries. The pharmaceutical company is one of the world's leaders in dermatology and parenteral treatment of thromboembolic disorders.

Link > Leo Pharma 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×